Share
448 Posts.
lightbulb Created with Sketch. 147
clock Created with Sketch.
13/12/21
16:42
Share
Originally posted by hottod:
↑
I think that MST Access is more likely to be right on this, as it was engaged by Neuren. MST states that the ACAD agreement includes “payments over CY22/23 on FDA approval and market entry”. Also, in the results conference last week, Jon Pilcher talked about expected payments based on the assumption that the FDA approves trofinetide and that the product is launched. It’s possible that NDA filing will trigger a payment, but it looks likely that the first payment will be due on FDA approval which, if all goes well, could be next November or December.
Expand
Hi hottod. I refer you to the webcast where JP is speaking. He makes it quite clear that the first milestone payment will be in early 2022.